Lecanemab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 757 publications

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Journal: Expert opinion on emerging drugs
Published: June 20, 2026

Anti-amyloid immunotherapies in Alzheimer's disease: Are future prescribers prepared? Insights of a French national survey.

Anti-amyloid immunotherapies in Alzheimer's disease: Are future prescribers prepared? Insights of a French national survey.

Journal: Journal of Alzheimer's disease : JAD
Published: June 04, 2026

Severe amyloid-related imaging abnormalities associated with lecanemab in Hong Kong: a case report.

Severe amyloid-related imaging abnormalities associated with lecanemab in Hong Kong: a case report.

Journal: Hong Kong medical journal = Xianggang yi xue za zhi
Published: June 04, 2026

Advances in Anti-Dementia Therapies in Older Adults

Advances in Anti-Dementia Therapies in Older Adults

Journal: Deutsche medizinische Wochenschrift (1946)
Published: May 29, 2026

New therapies and ongoing clinical trials in Alzheimer's disease

New therapies and ongoing clinical trials in Alzheimer's disease

Journal: Lakartidningen
Published: May 20, 2026

In vitro comparison of Aβ-targeting SNIPR, synNotch, and TRUCK for cell-based drug delivery in Alzheimer's disease.

In vitro comparison of Aβ-targeting SNIPR, synNotch, and TRUCK for cell-based drug delivery in Alzheimer's disease.

Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026

The social value of lecanemab for patients with early Alzheimer's disease in Japan.

The social value of lecanemab for patients with early Alzheimer's disease in Japan.

Journal: Journal of Alzheimer's disease : JAD
Published: May 11, 2026

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study.

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study.

Journal: Neurodegenerative disease management
Published: May 07, 2026

Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165.

Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165.

Journal: The journal of prevention of Alzheimer's disease
Published: April 21, 2026

Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.

Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.

Journal: Journal of Alzheimer's disease : JAD
Published: April 21, 2026

Integrative Analysis of Pharmacological and Non-pharmacological Interventions in Alzheimer's Dementia.

Integrative Analysis of Pharmacological and Non-pharmacological Interventions in Alzheimer's Dementia.

Journal: Cureus
Published: April 20, 2026

Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemab.

Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemab.

Journal: The journal of prevention of Alzheimer's disease
Published: April 20, 2026
Showing 1-12 of 757

Last Updated: 06/30/2026